Status:
COMPLETED
Primary Prevention of Hypertension in Obese Adolescents
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsors:
Baylor University
Conditions:
Obesity
Pre-Hypertension
Eligibility:
All Genders
11-18 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease...
Detailed Description
The trial will be a double blinded, placebo control trial of two uric acid lowering agents. The endpoints for this trial will be, endothelial function, systemic vascular resistance, plasma renin activ...
Eligibility Criteria
Inclusion
- Children between the ages of 11 and 18
- body mass index greater than the 95th percentile for age
- Blood pressure between 75th and 95th percentile for age, gender and height percentile
Exclusion
- hypertension at the time of screening
- allergy to one of the study medications
- liver function abnormality (AST or ALT greater than twice the upper limit of
- normal for the laboratory)
- history of renal stones
- renal insufficiency (Schwartz formula calculated GFR less than 70ml per min per 1.73m2 BSA)
- positive urine pregnancy test
- diabetes
- organ transplant recipient
- currently treated with an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), diuretic, other medications known to alter serum uric acid level
- lack of ability to comply with the study protocol
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00288158
Start Date
September 1 2008
End Date
January 1 2011
Last Update
September 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Children's Hospital
Houston, Texas, United States, 77030